Your browser is no longer supported. Please, upgrade your browser.
Settings
TAK Takeda Pharmaceutical Company Limited daily Stock Chart
TAK [NYSE]
Takeda Pharmaceutical Company Limited
Index- P/E24.93 EPS (ttm)0.81 Insider Own44.13% Shs Outstand3.15B Perf Week-0.15%
Market Cap63.78B Forward P/E13.76 EPS next Y1.47 Insider Trans0.00% Shs Float3.00B Perf Month1.00%
Income- PEG92.33 EPS next Q0.36 Inst Own- Short Float0.14% Perf Quarter16.73%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio2.94 Perf Half Y18.51%
Book/sh12.55 P/B1.61 EPS next Y- ROA- Target Price22.79 Perf Year16.00%
Cash/sh- P/C- EPS next 5Y0.27% ROE- 52W Range15.50 - 21.61 Perf YTD20.27%
Dividend0.83 P/FCF- EPS past 5Y- ROI- 52W High-6.39% Beta-
Dividend %4.10% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low30.52% ATR0.27
Employees49578 Current Ratio- Sales Q/Q88.30% Oper. Margin- RSI (14)55.78 Volatility0.84% 0.89%
OptionableYes Debt/Eq- EPS Q/Q11.20% Profit Margin- Rel Volume0.96 Prev Close20.32
ShortableYes LT Debt/Eq- EarningsNov 06 BMO Payout- Avg Volume1.40M Price20.23
Recom2.00 SMA20-0.86% SMA506.57% SMA20010.07% Volume1,338,540 Change-0.44%
Nov-01-19Initiated Cowen Market Perform $19.50
Aug-15-19Downgrade Daiwa Securities Outperform → Neutral
Dec-13-19 03:05PM  Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn's Disease Management PR Newswire
Dec-10-19 03:02PM  Biotech stocks are producing outsized gains heres how to get your share MarketWatch
Dec-09-19 10:00AM  Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019 Business Wire
10:00AM  Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting Business Wire
Dec-07-19 09:30AM  Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis Business Wire
Dec-06-19 03:07PM  Brandes Investments' Top 5 Buys in the 3rd Quarter GuruFocus.com
Dec-04-19 08:02PM  Is Takeda Pharmaceutical Company Limited (TAK) A Good Stock To Buy? Insider Monkey
Nov-25-19 08:38AM  Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting Business Wire
Nov-23-19 12:14PM  Longer-term data fail to clear concern over Takeda's dengue vaccine Reuters
10:30AM  Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting Business Wire
Nov-22-19 10:00PM  Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up Business Wire
10:00PM  CORRECTED-Takeda says cancer drug Alunbrig shows longer benefit vs crizotinib Reuters
10:16AM  Investors Hope for More From Takeda Than a Healthy Dividend GuruFocus.com
Nov-20-19 09:22AM  Myovant Up on Successful Completion of Prostate Cancer Study Zacks
Nov-14-19 01:27PM  Sarepta expands gene therapy push with $90M deal American City Business Journals
06:00AM  Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day Business Wire
Nov-13-19 09:06AM  Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3 Zacks
Nov-11-19 09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
Nov-08-19 07:58AM  New Analyses from the Phase 3 HELP Study Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period Business Wire
Nov-07-19 11:23AM  Takeda Takes a Big Step Into New Cancer Immunotherapy GuruFocus.com
08:00AM  Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation Business Wire
Nov-06-19 10:58PM  UPDATE 1-Takeda's dengue vaccine effective overall in study but with major limitation Reuters
05:00PM  Takeda's dengue vaccine effective overall in study but with major limitation Reuters
05:00PM  Takedas Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure Business Wire
12:00PM  Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting Business Wire
Nov-05-19 09:00AM  Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany Business Wire
07:00AM  Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform Business Wire
06:53AM  The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga
02:00AM  Takeda Continues Strategic Divestitures With Sale of Select OTC and Non-Core Assets to STADA for $660 Million USD Business Wire
Oct-31-19 02:00AM  Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year Business Wire
Oct-30-19 12:29PM  Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark Zacks
08:17AM  Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals
Oct-28-19 09:05AM  First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda's Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints PR Newswire
Oct-22-19 07:51AM  The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug Benzinga
01:00AM  Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study Business Wire
Oct-21-19 01:00AM  Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohns Disease Business Wire
Oct-18-19 06:30AM  Takeda pares down products and jobs, revives Genzyme building plans American City Business Journals
Oct-15-19 07:50AM  The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings Benzinga
04:08AM  UPDATE 1-Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino Reuters
03:36AM  Takeda sells Mideast, Africa drugs to Switzerland's Acino for around $200 mln Reuters
02:45AM  Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD Business Wire
Oct-11-19 09:37AM  Easy Investing Secrets to an Early Retirement - October 11, 2019 Zacks
05:07AM  Takeda Nears Russia, Mideast Asset Sale to Private Equity Bloomberg
Oct-10-19 11:24AM  Should You Avoid Takeda Pharmaceutical Company Limited (TAK)? Insider Monkey
Oct-09-19 09:39AM  Signs That Your Trading Will Ruin Your Retirement - October 09, 2019 Zacks
Oct-03-19 05:30PM  Here Is Hedge Funds 22nd Most Popular Stock Pick Insider Monkey
03:49PM  Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar Benzinga
Oct-01-19 06:56PM  As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets GuruFocus.com
Sep-26-19 02:28PM  Takeda Is Close to Selling Emerging Market, European Drugs Bloomberg
07:54AM  The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J Benzinga
Sep-25-19 08:15PM  New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1 Business Wire
05:00PM  First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab Business Wire
Sep-24-19 07:00AM  New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takedas TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection Business Wire
Sep-23-19 07:17PM  Investors May Want to Follow the Progress of These Biotechs GuruFocus.com
Sep-19-19 01:00AM  Takeda Recognized in the 2019 Dow Jones Sustainability World Index Business Wire
Sep-18-19 04:30AM  NICE Recommends Takhzyro®(Lanadelumab) for the Treatment of People Living with Rare Debilitating Genetic Disorder PR Newswire
Sep-17-19 10:39AM  Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks
Sep-06-19 07:27AM  The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication Benzinga
Sep-05-19 05:59PM  Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate PR Newswire
05:11PM  Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate CNW Group
Aug-21-19 08:40PM  Somerville's Finch raises $53M to develop bacteria pills for C.diff, autism American City Business Journals
Aug-16-19 09:30AM  Is Takeda (TAK) a Profitable Stock for Value Investors Now? Zacks
Jul-31-19 02:00AM  Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year Business Wire
02:00AM  Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration Business Wire
Jul-24-19 03:29PM  How Do Earnings Impact The Stock Market? Zacks
Jul-23-19 10:18AM  The AbbVie-Allergan Merger Is the Most Positive of the Pharma Deals Barrons.com
Jul-22-19 01:00AM  Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease Business Wire
Jul-17-19 12:57PM  Takeda kicks off sale of Western European drugs: sources Reuters
10:58AM  Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates Zacks
Jul-16-19 01:15PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-15-19 05:59PM  J&J Submits BLA for Subcutaneous Formulation of Darzalex Zacks
Jul-09-19 09:00PM  Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index Business Wire
02:15PM  Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
11:30AM  ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-08-19 02:00AM  Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A Business Wire
Jul-03-19 09:50AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
07:00AM  Takeda to Demonstrate Global Leadership in Hematology at ISTH 2019 Business Wire
Jul-02-19 11:53AM  Marshall Waces Return, AUM, and Holdings (Part II) Insider Monkey
11:30AM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-01-19 04:31PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK GlobeNewswire
02:20PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK) ACCESSWIRE
11:30AM  Takeda Completes Sale of Xiidra® to Novartis Business Wire
09:26AM  Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status Zacks
Jun-28-19 08:00PM  AbbVie Is Buying Allergan. Thats Not the Right Remedy for the Stock. Barrons.com
04:01PM  J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma Zacks
03:20PM  SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK PR Newswire
03:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK CNW Group
01:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK ACCESSWIRE
02:00AM  Pharma-owned plasma center set for major expansion in metro Phoenix American City Business Journals
Jun-27-19 08:05PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
06:45PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
04:49PM  T. Rowe Price Japan Fund Comments on Takeda Pharmaceutical GuruFocus.com
01:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK ACCESSWIRE
12:46PM  5 stocks trading at under $10 worth discovering MarketWatch
08:00AM  Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2018 Business Wire
05:22AM  Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention to Improve Health in Developing and Emerging Countries Business Wire
Jun-25-19 07:22PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
06:03PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Takeda Pharmaceutical Company Limited TAK Business Wire
04:36PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK GlobeNewswire
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. It provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. The company operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. Takeda Pharmaceutical Company Limited has licensing agreements with TESARO, Inc. for the commercialization of Niraparib, a poly ADP-ribose polymerase inhibitor; Denali Therapeutics for neurodegenerative disease therapeutic product candidates; and Wave Life Sciences Ltd. for central nervous system nucleic acid therapies. The company also has collaboration agreements with Rani Therapeutics LLC to conduct research on the use of the RANI PILL technology for oral delivery of Factor VIII therapy for patients with hemophilia A; Novimmune S.A. to develop and commercialize a bi-specific antibody to treat hemophilia A; and AB Biosciences Inc. for a recombinant immunoglobulin product candidate, as well as a strategic multi-target partnership with Sosei Group Corporation to discover, develop, and commercialize novel molecules, including small molecules and biologics. In addition, it has a strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; and research collaboration with Enzyre BV. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.